CPHI Frankfurt Report Predicts Huge Funding Overhang

New research from the CPHI Annual Report 2022 predicts that huge volumes of Venture Capital (VC) and Private Equity (PE) cash reserves will drive significant expansion in demand for CRO and CDMO services in the next two years.

Writing in the CPHI Annual Report, Brian Scanlan of Edgewater Capital says that, “Despite the economic and inflationary uncertainty, CRO and CDMOs are likely to be the chief beneficiaries of the investment capital that has poured into biotech during the last two years—with little slowdown in growth—despite the more challenging market conditions.”

His analysis predicts that CPHI Frankfurt exhibitors, and the wider contract services sector, will continue to see strong demand, as measured by historical standards—particularly as biotechs look to advance more targets. Additionally, the parked PE capital will support strong contract sector valuations and, more significantly, investment in CRO/CDMO infrastructure.

In fact, as of June of 2022, the U.S. private equity capital overhang was about $749 billion, with Venture Capital sat on a further $300 million. Significantly, Scanlan states that the current industry-predicted growth rates of 7.2% for CROs and 8.5% for CDMOs has failed to account for this parked capital.

“Putting pandemic-related factors aside, a significant portion of the heightened demand for CRO/CDMO services has been driven by VC-backed pharma and biopharma companies,” said Scanlan. “Presently, VC-funded biotechs are sitting on 2-3 years of cash reserves and this will ultimately transfer through, in part, to contract services. On top of this, biotech funding that has been raised over the last couple of years and is likely to be deployed relatively soon because these closed-end investment vehicles must be used in deals within 4-5 years.”

Looking at breakdown of the findings in more detail, smaller and medium CDMOs are forecast to see growth driven by the thousands of new compounds entering development, with larger CDMOs benefiting most from later phase compounds. Scanlan suggested the next few years could be particularly profitable for smaller CROs and CDMOs—whose services and culture closely match those of biotechs—if they invest and begin to scale as their clients advance into later phases.

The other significant factor driving investment is the ongoing preference for some re-shoring in supply chains, and this is likely be accelerated by recent geopolitical issues—the Russian/Ukraine conflict, EU energy concerns, and U.S.-China tensions—all creating uncertainty about moving vital materials around the globe.

The potential negatives for CDMOs include biotech desires to continue to husband cash in the short term spend, with CROs more involved in contract services proposals. Already, the average proposal value has started to drop as some biotechs are adding more stage gates to their projects in order to divide them into smaller chunks.

Orhan Caglayan, brand director at CPHI Frankfurt, said, “Our experts have identified some large and, until now, under-reported implications for CROs and CDMOs. Not only is the market very positive for the largest players—which is known—but also for the smaller contract services providers and specialists that rely upon CPHI Frankfurt to deliver new pharma network leads.”

To download a full copy of the CPHI Annual Report—featuring detailed insights from 12 experts and the findings from 400 survey global pharma executives, please visit HERE.